FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Cancer Immunol Immunother / Equine sarcoid: BCG immunotherapy compared to cryosurgery in...
Cancer immunology, immunotherapy : CII1986; 21(2); 133-140; doi: 10.1007/BF00199861

Equine sarcoid: BCG immunotherapy compared to cryosurgery in a prospective randomised clinical trial.

Abstract: A total of 30 horses with single or multiple sarcoid tumors of the skin were randomly divided into three treatment groups: (i) cryosurgical treatment, (ii) intralesional immunotherapy with a live BCG vaccine, (iii) intralesional immunotherapy with a BCG cell wall preparation. Complete tumour regression was obtained in all 10 cryosurgically treated horses, in 6 of 10 live BCG treated horses, and in 7 of 10 BCG cell wall treated horses. One live BCG and 2 BCG cell wall treated horses showed partial tumour regression of more than 50% of the tumour area. Eleven horses with sarcoid tumours were not eligible for random allocation in the trial because unfavourable site or size of the tumour precluded cryosurgical treatment. These animals were treated with BCG cell wall vaccine except for 1 animal, which was treated with live BCG. In 4 cases this treatment was combined with cytoreductive surgery of the tumour. In this prognostically unfavourable group 8 animals showed complete tumour regression and 3 animals did not respond. Regression after BCG immunotherapy appeared to correlate with size (larger tumours worse response) and localization of the sarcoid (less favourable results in the limb), and increase in peripheral blood leucocytes after the first injection. Horses with a positive delayed type hypersensitivity reaction to PPD before the start of treatment showed a tendency to more favourable prognosis than PPD negative horses. No correlation was present between regression and single or multiple presence of sarcoids, increase in body temperature after injection of BCG and the formation of specific antibodies to BCG. None of the cured animals have shown tumour recurrence 3 to 40 months following treatment.
Get Full Text
Publication Date: 1986-01-01 PubMed ID: 3633215DOI: 10.1007/BF00199861Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research compared three treatments for skin tumors in horses: cryosurgical treatment, intralesional immunotherapy with a live BCG vaccine, and intralesional immunotherapy with a BCG cell wall preparation. The results suggested that cryosurgical treatment was the most effective, although BCG immunotherapy also showed promise.

Study Design

  • The study involved 30 horses, all of whom had single or multiple sarcoid skin tumors. These horses were randomly assigned to one of three treatment groups.
  • The first group was treated with cryosurgery, a procedure that uses extreme cold to destroy abnormal tissue.
  • The second group received intralesional immunotherapy with a live BCG vaccine. This treatment involves injecting a live, attenuated (weakened) form of the bacteria that causes tuberculosis directly into the tumor. The aim is to stimulate an immune response that will attack the tumor cells.
  • The third group received intralesional immunotherapy with a BCG cell wall preparation. The cell wall preparation is made from components of the bacteria and is also intended to stimulate an immune response against the tumor.
  • Additionally, an “unfavorable” group of 11 horses with sarcoid tumors that were not suitable for cryosurgery received BCG cell wall vaccinations.

Results

  • All 10 horses in the cryosurgery group experienced complete tumor regression.
  • In the live BCG group and the BCG cell wall group, 6 out of 10 and 7 out of 10 horses respectively showed complete tumor regression. Some horses in these groups also showed partial tumor regression.
  • In the “unfavorable” group, 8 out of 11 horses showed complete tumor regression after treatment with the BCG cell wall vaccine.
  • Horses with larger tumors and tumors located on the limb tended to respond less well to BCG immunotherapy.
  • Horses that showed a positive delayed type hypersensitivity reaction to PPD (a diagnostic test for tuberculosis) before treatment started tended to have a more favorable prognosis.

Conclusions

  • The researchers concluded that while BCG immunotherapy can be effective in treating sarcoid tumors in horses, cryosurgery appeared to be the most effective treatment in their study.
  • They also found that tumor size, location, and the horse’s prior immune response may affect the tumor’s response to BCG immunotherapy.
  • Of significance, none of the horses that were “cured” showed any signs of tumor recurrence up to 40 months after treatment.

Cite This Article

APA
Klein WR, Bras GE, Misdorp W, Steerenberg PA, de Jong WH, Tiesjema RH, Kersjes AW, Ruitenberg EJ. (1986). Equine sarcoid: BCG immunotherapy compared to cryosurgery in a prospective randomised clinical trial. Cancer Immunol Immunother, 21(2), 133-140. https://doi.org/10.1007/BF00199861

Publication

Cancer immunology, immunotherapy : CII
ISSN: 0340-7004
NlmUniqueID: 8605732
Country: Germany
Language: English
Volume: 21
Issue: 2
Pages: 133-140

Researcher Affiliations

Klein, W R
    Bras, G E
      Misdorp, W
        Steerenberg, P A
          de Jong, W H
            Tiesjema, R H
              Kersjes, A W
                Ruitenberg, E J

                  MeSH Terms

                  • Animals
                  • Antibodies, Bacterial / biosynthesis
                  • BCG Vaccine / therapeutic use
                  • Cryosurgery
                  • Female
                  • Horse Diseases / therapy
                  • Horses
                  • Immunotherapy
                  • Male
                  • Skin Neoplasms / surgery
                  • Skin Neoplasms / therapy
                  • Skin Neoplasms / veterinary

                  References

                  This article includes 43 references
                  1. Sundberg JP, Burnstein T, Page EH, Kirkham WW, Robinson FR. Neoplasms of Equidae.. J Am Vet Med Assoc 1977 Jan 15;170(2):150-2.
                    pubmed: 576219
                  2. Watson RE Jr, Larson KA. Detection of tumor-specific antigens in an equine sarcoid cell line.. Infect Immun 1974 Apr;9(4):714-8.
                    pubmed: 4595759doi: 10.1128/iai.9.4.714-718.1974google scholar: lookup
                  3. Goodnight JE Jr, Morton DL. Immunotherapy from malignant disease.. Annu Rev Med 1978;29:231-83.
                    pubmed: 348035doi: 10.1146/annurev.me.29.020178.001311google scholar: lookup
                  4. Shapiro A, Kadmon D, Catalona WJ, Ratliff TL. Immunotherapy of superficial bladder cancer.. J Urol 1982 Nov;128(5):891-4.
                    pubmed: 6184490doi: 10.1016/s0022-5347(17)53265-6google scholar: lookup
                  5. Wyn-Jones G. Treatment of equine cutaneous neoplasia by radiotherapy using iridium 192 linear sources.. Equine Vet J 1983 Oct;15(4):361-5.
                    pubmed: 6641684doi: 10.1111/j.2042-3306.1983.tb01824.xgoogle scholar: lookup
                  6. Baldwin RW. Mechanisms of immunity in cancer.. Pathobiol Annu 1981;11:155-75.
                    pubmed: 6460216
                  7. Murphy JM, Severin GA, Lavach JD, Hepler DI, Lueker DC. Immunotherapy in ocular equine sarcoid.. J Am Vet Med Assoc 1979 Feb 1;174(3):269-72.
                    pubmed: 447557
                  8. Pimm MV, Baldwin RW. BCG therapy of pleural and peritoneal growth of transplanted rat tumours.. Int J Cancer 1975 Feb 15;15(2):260-9.
                    pubmed: 165155doi: 10.1002/ijc.2910150212google scholar: lookup
                  9. Piessens WF, Campbell M, Churchill WH. Inhibition or enhancement of rat mammary tumors dependent on dose BCG.. J Natl Cancer Inst 1977 Jul;59(1):207-11.
                    pubmed: 875054doi: 10.1093/jnci/59.1.207google scholar: lookup
                  10. Pascoe RR, Summers PM. Clinical survey of tumours and tumour-like lesions in horses in south east Queensland.. Equine Vet J 1981 Oct;13(4):235-9.
                    pubmed: 6459231doi: 10.1111/j.2042-3306.1981.tb03504.xgoogle scholar: lookup
                  11. de Jong WH, Steerenberg PA, Kreeftenberg JG, Tiesjema RH, Kruizinga W, van Noorle Jansen LM, Ruitenberg EJ. Experimental screening of BCG preparations produced for cancer immunotherapy: safety and immunostimulating and antitumor activity of four consecutively produced batches.. Cancer Immunol Immunother 1984;17(1):18-27.
                    pubmed: 6563941doi: 10.1007/BF00205492google scholar: lookup
                  12. Winston T, Rings M, Wyman M. Treatment of equine sarcoids.. J Am Vet Med Assoc 1979 Oct 15;175(8):775.
                    pubmed: 528320
                  13. Cotchin E. Veterinary oncology: a survey.. J Pathol 1984 Feb;142(2):101-27.
                    pubmed: 6366178doi: 10.1002/path.1711420202google scholar: lookup
                  14. Parr I. Response of syngeneic murine lymphomata to immunotherapy in relation to the antigenicity of the tumour.. Br J Cancer 1972 Jun;26(3):174-82.
                    pubmed: 5047141doi: 10.1038/bjc.1972.24google scholar: lookup
                  15. Hagenbeek A, Martens AC. BCG treatment of residual disease in acute leukemia: studies in a rat model for human acute myelocytic leukemia (BNML).. Leuk Res 1983;7(4):547-55.
                    pubmed: 6578394doi: 10.1016/0145-2126(83)90049-8google scholar: lookup
                  16. Fretz PB, Barber SM. Prospective analysis cryosurgery as the sole treatment for equine sarcoids.. Vet Clin North Am Small Anim Pract 1980 Nov;10(4):847-59.
                    pubmed: 6972661doi: 10.1016/s0195-5616(80)50085-9google scholar: lookup
                  17. Frauenfelder HC, Blevins WE, Page EH. Rn for treatment of periocular fibrous connective tissue sarcomas in the horse.. J Am Vet Med Assoc 1982 Feb 1;180(3):310-2.
                    pubmed: 7056684
                  18. Amtmann E, Müller H, Sauer G. Equine connective tissue tumors contain unintegrated bovine papilloma virus DNA.. J Virol 1980 Sep;35(3):962-4.
                    pubmed: 6252350doi: 10.1128/JVI.35.3.962-964.1980google scholar: lookup
                  19. Ragland WL, Spencer GR. Attempts to relate bovine papilloma virus to the cause of equine sarcoid: equidae inoculated intradermally with bovine papilloma virus.. Am J Vet Res 1969 May;30(5):743-52.
                    pubmed: 5813668
                  20. Parodi AL, Misdorp W, Mialot JP, Mialot M, Hart AA, Hurtrel M, Salomon JC. Intratumoral BCG and Corynebacterium parvum therapy of canine mammary tumours before radical mastectomy.. Cancer Immunol Immunother 1983;15(3):172-7.
                    pubmed: 6555059doi: 10.1007/BF00199160google scholar: lookup
                  21. Klein WR, Ruitenberg EJ, Steerenberg PA, de Jong WH, Kruizinga W, Misdorp W, Bier J, Tiesjema RH, Kreeftenberg JG, Teppema JS, Rapp HJ. Immunotherapy by intralesional injection of BCG cell walls or live BCG in bovine ocular squamous cell carcinoma: a preliminary report.. J Natl Cancer Inst 1982 Nov;69(5):1095-103.
                    pubmed: 6957655
                  22. Baldwin RW, Pimm MV. BGG immunotherapy of local subcutaneous growths and post-surgical pulmonary metastases of a transplanted rat epithelioma of spontaneous origin.. Int J Cancer 1973 Sep 15;12(2):420-7.
                    pubmed: 4792349doi: 10.1002/ijc.2910120213google scholar: lookup
                  23. Fazio M, Airoldi M, Negri L, Marchesa P, Gandolfo S. Specific immunological stimulation induced by cryosurgery in patients with squamous-cell carcinoma of the oral cavity.. J Maxillofac Surg 1984 Aug;12(4):153-6.
                    pubmed: 6590713doi: 10.1016/s0301-0503(84)80236-2google scholar: lookup
                  24. Zbar B, Rapp HJ, Ribi EE. Tumor suppression by cell walls of mycobacterium bovis attached to oil droplets.. J Natl Cancer Inst 1972 Mar;48(3):831-5.
                    pubmed: 4333775
                  25. Ribi EE, Meyer TJ, Azuma I, Zbar B. Mycobacterial cell wall components in tumor suppression and regression.. Natl Cancer Inst Monogr 1973 Dec;39:115-9.
                    pubmed: 4595311
                  26. Lane JG. The treatment of equine sarcoids by cryosurgery.. Equine Vet J 1977 Jul;9(3):127-33.
                    pubmed: 891516doi: 10.1111/j.2042-3306.1977.tb04003.xgoogle scholar: lookup
                  27. England JJ, Watson RE Jr, Larson KA. Virus-like particles in an equine sarcoid cell line.. Am J Vet Res 1973 Dec;34(12):1601-3.
                    pubmed: 4796998
                  28. Sparks FC. Hazards and complications of BCG immunotherapy.. Med Clin North Am 1976 May;60(3):499-509.
                    pubmed: 1271890doi: 10.1016/s0025-7125(16)31894-6google scholar: lookup
                  29. Kleinschuster SJ, Rapp HJ, Green SB, Bier J, van Kampen K. Efficacy of intratumorally administered mycobacterial cell walls in the treatment of cattle with ocular carcinoma.. J Natl Cancer Inst 1981 Nov;67(5):1165-71.
                    pubmed: 6946252
                  30. Wyman M, Rings MD, Tarr MJ, Alden CL. Immunotherapy in equine sarcoid: a report of two cases.. J Am Vet Med Assoc 1977 Sep 1;171(5):779-51.
                    pubmed: 332676
                  31. Lagrange PH, Thickstun PM. In vivo antitumor activity of various forms of delayed-type hypersensitivity in mice.. J Natl Cancer Inst 1979 Feb;62(2):429-36.
                    pubmed: 283275
                  32. Zbar B, Tanaka T. Immunotherapy of cancer: regression of tumors after intralesional injection of living Mycobacterium bovis.. Science 1971 Apr 16;172(3980):271-3.
                    pubmed: 4323415doi: 10.1126/science.172.3980.271google scholar: lookup
                  33. Hoffmann D, Jennings PA, Spradbrow PB. Immunotherapy of bovine ocular squamous cell carcinomas with phenol-saline extracts of allogenic carcinomas.. Aust Vet J 1981 Apr;57(4):159-62.
                    pubmed: 7271604doi: 10.1111/j.1751-0813.1981.tb00502.xgoogle scholar: lookup
                  34. Fatemi-Nainie S, Anderson LW, Cheevers WP. Identification of a transforming retrovirus from cultured equine dermal fibrosarcoma.. Virology 1982 Jul 30;120(2):490-4.
                    pubmed: 6179297doi: 10.1016/0042-6822(82)90050-2google scholar: lookup
                  35. Voss JL. Transmission of equine sarcoid.. Am J Vet Res 1969 Feb;30(2):183-91.
                    pubmed: 5392976
                  36. Mitchell MS, Murahata RI. Modulation of immunity by bacillus Calmette-Guérin (BCG).. Pharmacol Ther 1979;4(2):329-53.
                    pubmed: 386385doi: 10.1016/0163-7258(79)90141-4google scholar: lookup
                  37. Broström H, Bredberg-Rådén U, England J, Obel N, Perlmann P. Cell-mediated immunity in horses with sarcoid tumors against sarcoid cells in vitro.. Am J Vet Res 1979 Dec;40(12):1701-6.
                    pubmed: 525888
                  38. Joyce JR. Cryosurgery for removal of equine sarcoids.. Vet Med Small Anim Clin 1975 Feb;70(2):200-3.
                    pubmed: 1037772
                  39. Cheevers WP, Roberson SM, Brassfield AL, Davis WC, Crawford TB. Isolation of a retrovirus from cultured equine sarcoid tumor cells.. Am J Vet Res 1982 May;43(5):804-6.
                    pubmed: 7091844
                  40. Hilmas DE, Gillette EL. Radiotherapy of spontaneous fibrous connective-tissue sarcomas in animals.. J Natl Cancer Inst 1976 Feb;56(2):365-8.
                    pubmed: 1255767doi: 10.1093/jnci/56.2.365google scholar: lookup
                  41. Strafuss AC, Smith JE, Dennis SM, Anthony HD. Sarcoid in horses.. Vet Med Small Anim Clin 1973 Nov;68(11):1246-7.
                    pubmed: 4491121
                  42. Wyn-Jones G. Treatment of periocular tumours of horses using radioactive gold198 grains.. Equine Vet J 1979 Jan;11(1):3-10.
                    pubmed: 428361doi: 10.1111/j.2042-3306.1979.tb01283.xgoogle scholar: lookup
                  43. Cotchin E. A general survey of tumours in the horse.. Equine Vet J 1977 Jan;9(1):16-21.
                    pubmed: 319996doi: 10.1111/j.2042-3306.1977.tb03964.xgoogle scholar: lookup

                  Citations

                  This article has been cited 12 times.
                  1. Jindra C, Hainisch EK, Brandt S. Immunotherapy of Equine Sarcoids-From Early Approaches to Innovative Vaccines. Vaccines (Basel) 2023 Mar 30;11(4).
                    doi: 10.3390/vaccines11040769pubmed: 37112681google scholar: lookup
                  2. Saba C, Eggleston R, Parks A, Peroni J, Sjoberg E, Rice S, Tyma J, Williams J, Grosenbaugh D, Leard AT. ALVAC-fIL2, a feline interleukin-2 immunomodulator, as a treatment for sarcoids in horses: A pilot study. J Vet Intern Med 2022 May;36(3):1179-1184.
                    doi: 10.1111/jvim.16425pubmed: 35416353google scholar: lookup
                  3. Buddle BM, Vordermeier HM, Chambers MA, de Klerk-Lorist LM. Efficacy and Safety of BCG Vaccine for Control of Tuberculosis in Domestic Livestock and Wildlife. Front Vet Sci 2018;5:259.
                    doi: 10.3389/fvets.2018.00259pubmed: 30417002google scholar: lookup
                  4. Bogaert L, Woodham AW, Da Silva DM, Martens A, Meyer E, Kast WM. A novel murine model for evaluating bovine papillomavirus prophylactics/therapeutics for equine sarcoid-like tumours. J Gen Virol 2015 Sep;96(9):2764-2768.
                    doi: 10.1099/vir.0.000212pubmed: 26044793google scholar: lookup
                  5. Carstanjen B, Jordan P, Lepage OM. Carbon dioxide laser as a surgical instrument for sarcoid therapy--a retrospective study on 60 cases. Can Vet J 1997 Dec;38(12):773-6.
                    pubmed: 9426943
                  6. Broström H. Equine sarcoids. A clinical and epidemiological study in relation to equine leucocyte antigens (ELA). Acta Vet Scand 1995;36(2):223-36.
                    doi: 10.1186/BF03547691pubmed: 7484549google scholar: lookup
                  7. vd Meijden AP, Steerenberg PA, de Jong WH, Bogman MJ, Feitz WF, Hendriks BT, Debruyne FM, Ruitenberg EJ. The effects of intravesical and intradermal application of a new B.C.G. on the dog bladder. Urol Res 1986;14(4):207-10.
                    doi: 10.1007/BF00441115pubmed: 3787886google scholar: lookup
                  8. van der Meijden AP, de Jong WH, de Boer EC, Steerenberg PA, Debruyne FM, Ruitenberg EJ. Immunological aspects of intravesical administration of Bacillus Calmette-Guérin (BCG) in the guinea pig. Urol Res 1989;17(1):47-55.
                    doi: 10.1007/BF00261051pubmed: 2922891google scholar: lookup
                  9. De Jong WH, De Boer EC, Van der Meijden AP, Vegt P, Steerenberg PA, Debruyne FM, Ruitenberg EJ. Presence of interleukin-2 in urine of superficial bladder cancer patients after intravesical treatment with bacillus Calmette-Guérin. Cancer Immunol Immunother 1990;31(3):182-6.
                    doi: 10.1007/BF01744734pubmed: 2337907google scholar: lookup
                  10. Rutten VP, Klein WR, De Jong WA, Misdorp W, Steerenberg PA, De Jong WH, Den Otter W, Ruitenberg EJ. Immunotherapy of bovine ocular squamous cell carcinoma by repeated intralesional injections of live bacillus Calmette-Guérin (BCG) or BCG cell walls. Cancer Immunol Immunother 1991;34(3):186-90.
                    doi: 10.1007/BF01742311pubmed: 1756535google scholar: lookup
                  11. Monteiro MM, de Castro ELA, Pereira AJM, Thiesen R, Thiesen RMC, Salvarani FM. BCG Immunotherapy in Equine Sarcoid Treatment: Mechanisms, Clinical Efficacy, and Challenges in Veterinary Oncology. Viruses 2025 Sep 29;17(10).
                    doi: 10.3390/v17101322pubmed: 41157593google scholar: lookup
                  12. Spoormakers TJ, Klein WR, Jacobs JJ, Van Den Ingh TS, Koten JW, Den Otter W. Comparison of the efficacy of local treatment of equine sarcoids with IL-2 or cisplatin/IL-2. Cancer Immunol Immunother 2003 Mar;52(3):179-84.
                    doi: 10.1007/s00262-002-0369-0pubmed: 12649747google scholar: lookup
                  Subscribe to our newsletter
                  Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.